Risankizumab
- Generic Name
- Risankizumab
- Brand Names
- Skyrizi 150 Mg Dose Pack, Skyrizi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1612838-76-2
- Unique Ingredient Identifier
- 90ZX3Q3FR7
- Background
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. Risankizumab is being investigated for...
- Indication
Risankizumab is indicated to treat:
- Associated Conditions
- Moderate plaque-type psoriasis, Psoriasis, Psoriatic Arthritis, Severe Plaque Type Psoriasis, Active Psoriatic arthritis, Moderate, active Crohn´s Disease, Moderate, severe Psoriasis Vulgaris (Plaque Psoriasis), Severe, active Crohn´s Disease
- Associated Therapies
- -
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT05995353
- Locations
- 🇨🇦
London Health Sciences Center- University Hospital /ID# 258598, London, Ontario, Canada
🇺🇸Phoenix Children's Hospital /ID# 255766, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital /ID# 255762, Little Rock, Arkansas, United States
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 214
- Registration Number
- NCT05969223
- Locations
- 🇺🇸
U.S. Dermatology Partners Longview /ID# 266325, Longview, Texas, United States
🇺🇸Care Access - Danville /ID# 266300, Danville, Virginia, United States
🇺🇸Medical Dermatology Specialists /ID# 262915, Phoenix, Arizona, United States
A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 17
- Registration Number
- NCT05305222
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc /ID# 164197, Cypress, California, United States
A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 226
- Registration Number
- NCT05283681
- Locations
- 🇺🇸
Acpru /Id# 210844, Grayslake, Illinois, United States
🇺🇸PPD Clinical Research Unit - Austin /ID# 211456, Austin, Texas, United States
A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT05283694
- Locations
- 🇺🇸
Acpru /Id# 165737, Grayslake, Illinois, United States
High Dose Risankizumab for Psoriasis
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Oregon Medical Research Center
- Target Recruit Count
- 20
- Registration Number
- NCT05283135
- Locations
- 🇺🇸
Oregon Medical Research Center, Portland, Oregon, United States
Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT05274087
- Locations
- 🇺🇸
Acpru /Id# 223662, Grayslake, Illinois, United States
Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 394
- Registration Number
- NCT05274100
- Locations
- 🇺🇸
PPD Clinical Research Unit - Austin /ID# 222361, Austin, Texas, United States
🇺🇸Altasciences Clinical Los Angeles, Inc /ID# 222238, Cypress, California, United States
🇺🇸Anaheim Clinical Trials LLC /ID# 222821, Anaheim, California, United States
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT05268068
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital /ID# 212830, Shanghai, Shanghai, China
A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT05083078
- Locations
- 🇦🇹
Medical University Graz, Graz, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.